BMB-101 for absence epilepsy and DEE
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests a new drug called BMB-101 for people with absence epilepsy (including Jeavons syndrome) or developmental epileptic encephalopathies (DEE) like Dravet or Lennox-Gastaut. It aims to see if the drug can reduce seizure frequency and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of absence epilepsy (with or without eyelid jerks) or a developmental and epileptic encephalopathy (DEE) like Dravet or Lennox-Gastaut.
- You are between 18 and 65 years old.
- You have tried at least one seizure medicine and have been on a stable dose of your current seizure medicines for at least 4 weeks.
- You are willing to use effective birth control if you or your partner could become pregnant, and for 90 days after the last dose.
- You do not have serious heart, liver, or kidney problems, or a history of stroke or heart attack.
- You are not currently taking certain medications like fenfluramine, antidepressants, or antipsychotics.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests how safe ETX101 is and whether it can help reduce seizures in young children with Dravet syndrome caused by an SCN1A gene change. It mainly enrolls infants and children with a specific type of seizure history and genetic result.
This trial tests an investigational medicine called CBD-OS for people with a type of severe epilepsy called developmental and epileptic encephalopathy (DEE). The study aims to see if this treatment is safe and helps control seizures.
This trial tests a medication called LP352 for children and adults with certain types of epilepsy (Dravet syndrome, Lennox-Gastaut syndrome, or other developmental and epileptic encephalopathies). It's for people who already completed a previous study of LP352 and may benefit from continued treatment.
This study tests a new medicine (S230815) given by lumbar puncture (spinal tap) to see if it helps reduce seizures in children with a specific genetic cause of epilepsy. It is for children aged 2 to 12 who have not responded well to other treatments.
This trial tests a new medication, CB03-154, to see if it is safe and can reduce seizures in adults with focal epilepsy. You may be able to join if you have had focal epilepsy for at least 2 years and are on a stable dose of 1 to 3 anti-seizure medications.
This trial tests XEN1101 compared with a placebo (inactive pill) in people with focal-onset seizures that haven’t been fully controlled despite trying at least two anti-seizure medicines. If you qualify, you may help researchers see whether the study drug reduces seizure frequency and improves control.
Hear when a new Dravet Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.